GONADOTROPIN-RELEASING HORMONE/LOW-DOSE STEROIDS NOT APPROPRIATE FOR STUDY IN BREAST CANCER HIGH RISKS -- FDA CMTE.; AGENCY WILL WORK TO REVISE PROTOCOL
Executive Summary
Gonadotropin-releasing hormone agonist (GnRHA) and a low-dose conjugated estrogens oral contraceptive should not move into larger clinical trials for women at high risk of breast cancer based on the results of a pilot study, FDA's Fertility & Maternal Health Advisory Committee concluded June 24.